Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition

I. A. Schepetkin, A. I. Khlebnikov, M. P. Giovannoni, L. N. Kirpotina, A. Cilibrizzi, M. T. Quinn

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure-activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.

Original languageEnglish
Pages (from-to)1478-1504
Number of pages27
JournalCurrent Medicinal Chemistry
Volume21
Issue number13
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Formyl Peptide Receptor
Molecular modeling
Ligands
Molecules
Phenylurea Compounds
Pyrazolones
Benzimidazoles
Neurodegenerative diseases
Structure-Activity Relationship
G-Protein-Coupled Receptors
Innate Immunity
Neurodegenerative Diseases
Cataract
Atherosclerosis
Screening
Derivatives
Therapeutics

Keywords

  • Agonist
  • Chiral recognition
  • Formyl peptide receptor
  • G protein-coupled receptor
  • Molecular modeling
  • Neutrophil

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition. / Schepetkin, I. A.; Khlebnikov, A. I.; Giovannoni, M. P.; Kirpotina, L. N.; Cilibrizzi, A.; Quinn, M. T.

In: Current Medicinal Chemistry, Vol. 21, No. 13, 2014, p. 1478-1504.

Research output: Contribution to journalReview article

@article{b7a1d5b9663f46d6929c8916af00ca57,
title = "Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition",
abstract = "Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure-activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.",
keywords = "Agonist, Chiral recognition, Formyl peptide receptor, G protein-coupled receptor, Molecular modeling, Neutrophil",
author = "Schepetkin, {I. A.} and Khlebnikov, {A. I.} and Giovannoni, {M. P.} and Kirpotina, {L. N.} and A. Cilibrizzi and Quinn, {M. T.}",
year = "2014",
doi = "10.2174/0929867321666131218095521",
language = "English",
volume = "21",
pages = "1478--1504",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition

AU - Schepetkin, I. A.

AU - Khlebnikov, A. I.

AU - Giovannoni, M. P.

AU - Kirpotina, L. N.

AU - Cilibrizzi, A.

AU - Quinn, M. T.

PY - 2014

Y1 - 2014

N2 - Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure-activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.

AB - Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure-activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.

KW - Agonist

KW - Chiral recognition

KW - Formyl peptide receptor

KW - G protein-coupled receptor

KW - Molecular modeling

KW - Neutrophil

UR - http://www.scopus.com/inward/record.url?scp=84899864401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899864401&partnerID=8YFLogxK

U2 - 10.2174/0929867321666131218095521

DO - 10.2174/0929867321666131218095521

M3 - Review article

VL - 21

SP - 1478

EP - 1504

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 13

ER -